For these reasons, in the clinical practice, the KRAS mutation status, obtained by specimens analysis of the primary colorectal tumor (tumor biopsy or colorectal resection) represents one of the most important driver for the chemotherapy regimen choice, for the type of targeting agent to be administered in association with chemotherapy and for the subsequent surgical plan. This evidence concerns the gene KRAS and neoplasm.